Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.6
5.4
Journals
Marine Drugs
Special Issues
Marine Lectins
share announcement

Marine Lectins

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 8274

Special Issue Editor

Prof. Dr. Kanji Hori

E-Mail Website
Guest Editor
Graduate School of Integrated Sciences for Life, Hiroshima University, Kagamiyama 1-4-4, Higashi-Hiroshima 739-8528, Japan
Interests: algal lectins; structures; functions; applications; marine glycoscience; marine biotechnology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Lectins function as recognition molecules of carbohydrate structures in glycoconjugates on cell surfaces or in bodily fluids, which also enable carbohydrate-binding proteins to be used in the application fields of healthcare, including drugs, nutraceutical, and medical devices. Although lectins are ubiquitous proteins in organisms with an evolutional relationship in some instances, their biochemical properties, such as structures and carbohydrate recognition mode, are generally different dependent on the derived organisms. Increasing information has recently emerged on novel lectins with unique structures and bioactivities from marine organisms, as seen in antiviral algal lectins. This Special Issue aims to exchange and share research results on lectins from marine organisms ranging from viruses to mammals, and to obtain a comprehensive understanding of the structures, functions, and applications of the fruitful target of “marine lectins”. We look forward to receiving your contributions to this issue.

Prof. Dr. Kanji Hori
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Lectins
  • Marine organisms
  • Molecular structures
  • Carbohydrate-binding specificity
  • Biofunction
  • Biological activity
  • Healthcare
  • Drugs
  • Nutraceutical
  • Medical device

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 2196 KiB  
Article
Oncolytic Vaccinia Virus Harboring Aphrocallistes vastus Lectin Inhibits the Growth of Hepatocellular Carcinoma Cells
by Riqing Jiang, Yufeng Qiu, Xiaomei Zhang, Ningning Zhou, Xiaoyuan Jia, Kan Chen, Yanrong Zhou, Ting Ye and Gongchu Li
Mar. Drugs 2022, 20(6), 378; https://doi.org/10.3390/md20060378 - 04 Jun 2022
Cited by 5 | Viewed by 2274
Abstract
Oncolytic vaccinia virus has been developed as a novel cancer therapeutic drug in recent years. Our previous studies demonstrated that the antitumor effect of oncolytic vaccina virus harboring Aphrocallistes vastus lectin (oncoVV-AVL) was significantly enhanced in several cancer cells. In the present study, [...] Read more.
Oncolytic vaccinia virus has been developed as a novel cancer therapeutic drug in recent years. Our previous studies demonstrated that the antitumor effect of oncolytic vaccina virus harboring Aphrocallistes vastus lectin (oncoVV-AVL) was significantly enhanced in several cancer cells. In the present study, we investigated the underlying mechanisms of AVL that affect virus replication and promote the antitumor efficacy of oncolytic virus in hepatocellular carcinoma (HCC). Our results showed that oncoVV-AVL markedly exhibited antitumor effects in both hepatocellular carcinoma cell lines and a xenograft mouse model. Further investigation illustrated that oncoVV-AVL could activate tumor immunity by upregulating the expression of type I interferons and enhance virus replication by inhibiting ISRE mediated viral defense response. In addition, we inferred that AVL promoted the ability of virus replication by regulating the PI3K/Akt, MAPK/ERK, and Hippo/MST pathways through cross-talk Raf-1, as well as metabolism-related pathways. These findings provide a novel perspective for the exploitation of marine lectins in oncolytic therapy. Full article
(This article belongs to the Special Issue Marine Lectins)
►▼ Show Figures

Figure 1

10 pages, 2620 KiB  
Article
Oncolytic Vaccinia Virus Harboring Aphrocallistes vastus Lectin Inhibits the Growth of Cervical Cancer Cells Hela S3
by Jiajun Ni, Hualin Feng, Xiang Xu, Tingting Liu, Ting Ye, Kan Chen and Gongchu Li
Mar. Drugs 2021, 19(10), 532; https://doi.org/10.3390/md19100532 - 23 Sep 2021
Cited by 9 | Viewed by 1694
Abstract
Aphrocallistes vastus lectin (AVL) is a C-type marine lectin produced by sponges. Our previous study demonstrated that genes encoding AVL enhanced the cytotoxic effect of oncolytic vaccinia virus (oncoVV) in a variety of cancer cells. In this study, the inhibitory effect of oncoVV-AVL [...] Read more.
Aphrocallistes vastus lectin (AVL) is a C-type marine lectin produced by sponges. Our previous study demonstrated that genes encoding AVL enhanced the cytotoxic effect of oncolytic vaccinia virus (oncoVV) in a variety of cancer cells. In this study, the inhibitory effect of oncoVV-AVL on Hela S3 cervical cancer cells, a cell line with spheroidizing ability, was explored. The results showed that oncoVV-AVL could inhibit Hela S3 cells growth both in vivo and in vitro. Further investigation revealed that AVL increased the virus replication, promote the expression of OASL protein and stimulated the activation of Raf in Hela S3 cells. This study may provide insight into a novel way for the utilization of lection AVL. Full article
(This article belongs to the Special Issue Marine Lectins)
►▼ Show Figures

Figure 1

Review

Jump to: Research

21 pages, 2205 KiB  
Review
Algal and Cyanobacterial Lectins and Their Antimicrobial Properties
by José Abel Fernández Romero, María Gabriela Paglini, Christine Priano, Adolfina Koroch, Yoel Rodríguez, James Sailer and Natalia Teleshova
Mar. Drugs 2021, 19(12), 687; https://doi.org/10.3390/md19120687 - 01 Dec 2021
Cited by 11 | Viewed by 3607
Abstract
Lectins are proteins with a remarkably high affinity and specificity for carbohydrates. Many organisms naturally produce them, including animals, plants, fungi, protists, bacteria, archaea, and viruses. The present report focuses on lectins produced by marine or freshwater organisms, in particular algae and cyanobacteria. [...] Read more.
Lectins are proteins with a remarkably high affinity and specificity for carbohydrates. Many organisms naturally produce them, including animals, plants, fungi, protists, bacteria, archaea, and viruses. The present report focuses on lectins produced by marine or freshwater organisms, in particular algae and cyanobacteria. We explore their structure, function, classification, and antimicrobial properties. Furthermore, we look at the expression of lectins in heterologous systems and the current research on the preclinical and clinical evaluation of these fascinating molecules. The further development of these molecules might positively impact human health, particularly the prevention or treatment of diseases caused by pathogens such as human immunodeficiency virus, influenza, and severe acute respiratory coronaviruses, among others. Full article
(This article belongs to the Special Issue Marine Lectins)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop